fda bpc-157 immunogenicity concerns Peptide Therapy for Inflammation: A New Solution FDA Briefing Document Pharmacy Compounding

Peptides are generally well-tolerated, especially when prescribed appropriately

April 14, 2026 Cagrilintide long term weight maintenance research covering chronic body composition, metabolic stability, combined cagrisema dosing, and rodent obesity model outcomes

By potentially lengthening these telomeres, Epithalon may contribute to extended cellular life and hence, play a critical role in longevity research

As noted, that distinction is important: Category 1 is the more permissive interim bucket for substances the FDA is evaluating for inclusion on the 503A bulks list, while Category 2 is reserved for substances the agency has identified as presenting significant safety risks